Publications

Journal Article
Research Support, Non-U.S. Gov't
Epublish 26 citations
Electronic publication date
November 21, 2013

View on Pubmed.gov 24252631 | View on doi.org 10.1186/2051-59...

Protective effects of decay-accelerating factor on blast-induced neurotrauma in rats.

Search for publications in this journal Acta Neuropathol Commun

Abstract

BACKGROUND

Blast-induced neurotrauma (BINT) is the signature life threatening injury of current military casualties. Neuroinflammation is a key pathological occurrence of secondary injury contributing to brain damage after blast injury. We have recently demonstrated that blast-triggered complement activation and cytokine release are associated with BINT. Here, we evaluated if administration of the complement inhibitor recombinant human decay-accelerating factor (rhDAF) is beneficial on neuroinflammation and neurodegeneration in a rat model of moderate BINT. Administration of rhDAF after exposure to moderate blast overpressure (BOP, 120 kPa) mitigated brain injury characterized by neuronal degeneration. rhDAF treatment reduced complement hemolytic activity at 3 hours and tissue complement deposition at 3, 24, and 48 hours as well as systemic and local cytokine release at 24 hours post BOP. Furthermore, rhDAF protected blood-brain barrier (BBB) integrity and reduced cytotoxic edema. Interaction between complement cleavage component, C3a and C3a receptor and tau phosphorylation were also attenuated in rhDAF treated animals at 3 and 24 hours after BOP. These novel findings suggest early complement targeted inhibition as a new therapeutic strategy to decrease neuroinflammation and neurodegeneration after blast TBI.

RESULT

Administration of rhDAF after exposure to moderate blast overpressure (BOP, 120 kPa) mitigated brain injury characterized by neuronal degeneration. rhDAF treatment reduced complement hemolytic activity at 3 hours and tissue complement deposition at 3, 24, and 48 hours as well as systemic and local cytokine release at 24 hours post BOP. Furthermore, rhDAF protected blood-brain barrier (BBB) integrity and reduced cytotoxic edema. Interaction between complement cleavage component, C3a and C3a receptor and tau phosphorylation were also attenuated in rhDAF treated animals at 3 and 24 hours after BOP.

CONCLUSION

These novel findings suggest early complement targeted inhibition as a new therapeutic strategy to decrease neuroinflammation and neurodegeneration after blast TBI.

References

Sci Transl Med. 2012 May 16;4(134):134ra60

J Neuroinflammation. 2012;9:137

Neuroscience. 2010 Jul 28;168(4):1036-46

J Neurol Sci. 2012 Jul 15;318(1-2):146-54

Cited by 26 citations (total)

Journal Article Review

Vascular and inflammatory factors in the pathophysiology of blast-induced brain injury.

Electronic publication date April 9, 2015

Search for publications in this journal Front Neurol

Gregory A Elder [...] Stephen T Ahlers et al.

Blast-related traumatic brain injury (TBI) has received much recent attention because of its frequency in the conflicts in Iraq and...

Journal Article

Decay-Accelerating Factor Creates an Organ-Protective Phenotype after Hemorrhage in Conscious Rats.

Electronic publication date November 15, 2022

Search for publications in this journal Int J Mol Sci

Milomir O Simovic [...] Yansong Li et al.

Preclinical and clinical studies have shown that traumatic hemorrhage (TH) induces early complement cascade activation, leading to inflammation-associated multiple-organ dysfunction...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances